SCHEMBL7095359

SCHEMBL7095359

CC(=O)c1cnccc1NC(=O)C(C)(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.57
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
KDM4E B2RXH2 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
PDK1 Q15118 1/20 0.43
PDK2 Q15119 1/20 0.43
PDK3 Q15120 1/20 0.43
PDK4 Q16654 1/20 0.43
LMNA P02545 2/20 0.42
CETP P11597 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
AAK1 Q2M2I8 1/20 0.40
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5739797 0.84 TSHR (0.51) TSHRNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL31145849 0.82 TSHR (0.49) TSHRNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL12190376 0.80 NAMPT (0.49) TSHRRAB9A
SCHEMBL4153508 0.80 TSHR (0.49) TSHRNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL1190850 0.80 TSHR (0.49) TSHRNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL31563528 0.79 KDM4C (0.59) KDM4EL3MBTL1LMNAROCK2ROCK1
SCHEMBL12990781 0.79 KDM4C (0.59) KDM4EL3MBTL1LMNAROCK2ROCK1
SCHEMBL3899443 0.79 TSHR (0.48) TSHRNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL5918078 0.79 TSHR (0.48) TSHRNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL12750476 0.79 TSHR (0.55) TSHRNPC1RAB9ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0842924-A1 Pyridine intermediates, useful in the synthesis of beta-adrenergic receptor agonists PFIZER INC. (US) 1998-05-20 EP claimed
EP-4688748-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2026-02-11 EP disclosed
US-20260008774-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2026-01-08 US disclosed
US-12448369-B2 Quinolinone amide compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-10-21 US disclosed
US-20250026740-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-01-23 US disclosed
WO-2024206339-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2024-10-03 WO disclosed
EP-0842924-B1 Pyridine intermediates, useful in the synthesis of beta-adrenergic receptor agonists PFIZER (US) 2003-08-20 EP disclosed
US-6031105-A Substituted pyridines PFIZER INC (US) 2000-02-29 US disclosed
US-6008361-A Substituted pyridines PFIZER INC. (US) 1999-12-28 US disclosed
EP-0842924-A1 Pyridine intermediates, useful in the synthesis of beta-adrenergic receptor agonists PFIZER INC. (US) 1998-05-20 EP disclosed
EP-0480155-B1 4-Substituted dihydropyrido (4,3-d)pyrimidines as analgesics and topical antiinflammatory agents for the treatment of skin disorders HOECHST ROUSSEL PHARMA (US) 1996-01-31 EP disclosed
EP-0480155-A2 4-Substituted dihydropyrido (4,3-d)pyrimidines as analgesics and topical antiinflammatory agents for the treatment of skin disorders HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1992-04-15 EP disclosed
US-5095019-A 4-substituted dihydropyrido(4,3-D)pyrimidines as analgesics and topical antiinflammatory agents for the treatment of skin disorders HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1992-03-10 US disclosed
US-5059602-A 4-substituted dihydropyrido(4,3-d)pyrimidines as analgesics and topical antiinflammatory agents for the treatment of skin disorders HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
EP-0435222-A2 Aminopyridinylmethanols and aminomethylpyridinamines and related compounds, a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1991-07-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12448369-B2 Quinolinone amide compounds and uses thereof TNNI3, TNNT2, COQ8A TSHR 3265/4885NPC1 1533/4885RAB9A 288/4885
US-20250026740-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, COQ8A TSHR 3265/4885NPC1 1533/4885RAB9A 288/4885
US-20260008774-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF TNNT2, TNNI3, TNNC1 TSHR 339/4885NPC1 304/4885RAB9A 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.